Dual-targeted NIR-II AIE theranostic nanoparticles disrupt HNRNPC-driven ITGA1+ myCAFs differentiation and immune evasion in oral squamous cell carcinoma - PubMed
3 days ago
- #Photodynamic Therapy
- #Oral Squamous Cell Carcinoma
- #Theranostic Nanoparticles
- Dual-targeted NIR-II AIE theranostic nanoparticles (NPs-H-I) disrupt HNRNPC-driven ITGA1+ myCAFs differentiation and immune evasion in oral squamous cell carcinoma (OSCC).
- HNRNPC identified as a driver of OSCC progression via glycolysis and TGF-β-mediated differentiation of ITGA1+ myCAFs, leading to CD8+ T cell exhaustion.
- NPs-H-I enable precise NIR-II imaging and photodynamic therapy (PDT), selectively targeting HNRNPC-high tumor cells and ITGA1+ myCAFs.
- Therapy with NPs-H-I inhibits tumor growth and restores anti-tumor immunity in murine models.
- The study establishes the HNRNPC-ITGA1 axis as a metabolic-immune checkpoint in OSCC and introduces a translatable precision medicine platform.